Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey A Johnson

Showing results (1-10 of 469) with videos related to

Pageof 47
Sort By:
Diabetologia|October 18, 2014
The safety of sulfonylurea therapy in type 2 diabetes: have we reached the practical limits of our evidence base?Jeffrey A Johnson
Nature Aging|April 28, 2023
Myths about digital technology and older adultsJeffrey A Johnson
Recent Patents on CNS Drug Discovery|June 30, 2012
The Nrf2-ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseasesGururaj Joshi, Jeffrey A Johnson
Asia-Pacific Journal of Public Health|April 14, 2012
Relationship between duration of type 2 diabetes and self-reported participation in diabetes education in KoreaJongnam Hwang, Jeffrey A Johnson
Biochimica Et Biophysica Acta|January 3, 2014
Oxidative damage and the Nrf2-ARE pathway in neurodegenerative diseasesLi Gan, Jeffrey A Johnson
Physiological Genomics|June 5, 2002
Time-dependent changes in ARE-driven gene expression by use of a noise-filtering process for microarray dataJiang Li, Jeffrey A Johnson
Antimicrobial Agents and Chemotherapy|May 23, 2003
Alpha interferon augments cidofovir's antiviral and antiproliferative activitiesJeffrey A Johnson, J David Gangemi
Plos One|August 8, 2013
Mechanisms of Nrf2 protection in astrocytes as identified by quantitative proteomics and siRNA screeningJames A Dowell, Jeffrey A Johnson
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|June 21, 2006
Evidence and advocacy: are all things considered?Jeffrey A Johnson, Alun L Edwards
Diabetes Research and Clinical Practice|September 11, 2012
Balancing the risks and benefits for pioglitazone in type 2 diabetesJeffrey A Johnson, Isabelle N Colmers
Pageof 47

Showing results (1-10 of 469) with videos related to

Sort By:
Pageof 47
Diabetologia|October 18, 2014
The safety of sulfonylurea therapy in type 2 diabetes: have we reached the practical limits of our evidence base?Jeffrey A Johnson
Nature Aging|April 28, 2023
Myths about digital technology and older adultsJeffrey A Johnson
Recent Patents on CNS Drug Discovery|June 30, 2012
The Nrf2-ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseasesGururaj Joshi, Jeffrey A Johnson
Asia-Pacific Journal of Public Health|April 14, 2012
Relationship between duration of type 2 diabetes and self-reported participation in diabetes education in KoreaJongnam Hwang, Jeffrey A Johnson
Biochimica Et Biophysica Acta|January 3, 2014
Oxidative damage and the Nrf2-ARE pathway in neurodegenerative diseasesLi Gan, Jeffrey A Johnson
Physiological Genomics|June 5, 2002
Time-dependent changes in ARE-driven gene expression by use of a noise-filtering process for microarray dataJiang Li, Jeffrey A Johnson
Antimicrobial Agents and Chemotherapy|May 23, 2003
Alpha interferon augments cidofovir's antiviral and antiproliferative activitiesJeffrey A Johnson, J David Gangemi
Plos One|August 8, 2013
Mechanisms of Nrf2 protection in astrocytes as identified by quantitative proteomics and siRNA screeningJames A Dowell, Jeffrey A Johnson
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|June 21, 2006
Evidence and advocacy: are all things considered?Jeffrey A Johnson, Alun L Edwards
Diabetes Research and Clinical Practice|September 11, 2012
Balancing the risks and benefits for pioglitazone in type 2 diabetesJeffrey A Johnson, Isabelle N Colmers
Pageof 47